{"words": ["provide", "pilot", "data", "safety", "efficacy", "egb", "761", "patients", "aged", "80", "older", "retrospective", "analysis", "compared", "treatment", "outcomes", "egb", "761", "donepezil", "12", "months", "189", "patients", "aged", "80", "years", "older", "suffering", "alzheimer", "disease", "ad", "12", "months", "significant", "difference", "cognitive", "decline", "measured", "state", "examination", "mmse", "score", "donepezil", "egb", "761", "p", "found", "adverse", "events", "donepezil", "suggest", "similar", "effects", "cognitive", "symptoms", "use", "egb", "761", "treatment", "dementia", "ad", "together", "favorable", "safety", "compared", "donepezil"], "authors": [["Rapp", "Michael", "M", null], ["Burkart", "Martin", "M", null], ["Kohlmann", "Thomas", "T", null], ["Bohlken", "Jens", "J", null]], "title": "Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer's dementia in very old age: A retrospective observational study.", "year": null, "sentences": ["To provide pilot data for the safety and efficacy of EGb 761 in the oldest-old patients (aged 80 or older).In a retrospective analysis, we compared treatment outcomes with EGb 761 or donepezil over 12\u00a0months in 189\u00a0patients aged 80\u00a0years or older suffering from Alzheimer's disease (AD).Over 12\u00a0months, there was no significant difference in cognitive decline, measured with the mini-mental state examination (MMSE) score, between donepezil and EGb 761 (p\u00a0=\u00a00.31).", "We found more adverse events in the donepezil group.Results suggest similar effects on cognitive symptoms from the use of EGb 761 in the treatment of dementia in AD together with favorable safety compared to donepezil.", "."], "id": "29319499", "text": "To provide pilot data for the safety and efficacy of EGb 761 in the oldest-old patients (aged 80 or older).In a retrospective analysis, we compared treatment outcomes with EGb 761 or donepezil over 12\u00a0months in 189\u00a0patients aged 80\u00a0years or older suffering from Alzheimer's disease (AD).Over 12\u00a0months, there was no significant difference in cognitive decline, measured with the mini-mental state examination (MMSE) score, between donepezil and EGb 761 (p\u00a0=\u00a00.31). We found more adverse events in the donepezil group.Results suggest similar effects on cognitive symptoms from the use of EGb 761 in the treatment of dementia in AD together with favorable safety compared to donepezil.\u2029.", "doi": "10.5414/CP203103", "journal": ["International journal of clinical pharmacology and therapeutics", "Int J Clin Pharmacol Ther"], "date": "2018-01-18_23:41:05"}